SecProbe.io

Filing text and metadata
Intelligence Terminal Search Probe Scores Topics IPO Watchlist Monthly Activity About API

SEC Comment Letter for Theriva Biologics, Inc. (TOVX) (CIK 0000894158) (TOVX) — Jan 24, 2007

Theriva Biologics, Inc. (TOVX) (CIK 0000894158)
Date: Jan. 24, 2007 · CIK: 0000894158 · Accession: 0000000000-07-003659

AI Filing Summary & Sentiment

Sentiment
Urgency
Document Type
Confidence
SEC Posture
Company Posture

Summary

Reasoning

File numbers found in text: 333-139354

Date
January 24, 2007
Author
Jeffrey P. Riedler
Form
UPLOAD
Company
Theriva Biologics, Inc. (TOVX) (CIK 0000894158)

Letter

Mail Stop 6010 January 24, 2007 Mr. Steve H. Kanzer Chief Executive Officer Pipex Pharmaceuticals, Inc. 3985 Research Park Drive Ann Arbor, MI 48108

Re: Pipex Pharmaceuticals, Inc. Registration Statement on Form SB-2 Filed on December 14, 2006 File Number 333-139354

Dear Mr. Kanzar:

We have received your response letter da ted January 5, 2007 and have the following additional comment. 1. Please provide us your analysis as to whethe r you consider Ridgeback Capital Investment Ltd. to be an “affiliate” of the Company. We may have further comments after receiving your response.

* * *

Mr. Steve H. Kanzer Pipex Pharmaceuticals, Inc. January 24, 2007 Page 2 Please furnish a letter on EDGAR under the form type label CORRESP in response to our comment. Detailed letters greatly facilitate our review. Please contact Sonia Barros at (202) 551-3655 with any questions.

S i n c e r e l y ,

J e f f r e y P . R i e d l e r A s s i s t a n t D i r e c t o r

cc: Hank Gracin, Esq. Lehman & Eilen LLP Mission Bay Office Plaza Suite 300 20283 State Road 7 Boca Raton, FL 33498

Show Raw Text
Mail Stop 6010

       January 24, 2007

Mr. Steve H. Kanzer
Chief Executive Officer Pipex Pharmaceuticals, Inc. 3985 Research Park Drive Ann Arbor, MI 48108

Re: Pipex Pharmaceuticals, Inc.
  Registration Statement on Form SB-2
  Filed on December 14, 2006
  File Number 333-139354

Dear Mr. Kanzar:

We have received your response letter da ted January 5, 2007 and have the following
additional comment.
1. Please provide us your analysis as to whethe r you consider Ridgeback Capital Investment
Ltd. to be an “affiliate” of the Company.  We  may have further comments after receiving
your response.

* * *

Mr. Steve H. Kanzer
Pipex Pharmaceuticals, Inc.
January 24, 2007 Page 2
Please furnish a letter on EDGAR under the form type label CORRESP in response to
our comment.  Detailed letters greatly facilitate  our review.  Please contact Sonia Barros at (202)
551-3655 with any questions.

       S i n c e r e l y ,

       J e f f r e y  P .  R i e d l e r
       A s s i s t a n t  D i r e c t o r

cc: Hank Gracin, Esq.
Lehman & Eilen LLP Mission Bay Office Plaza Suite 300 20283 State Road 7 Boca Raton, FL 33498